"Urothelium" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The epithelial lining of the URINARY TRACT.
Descriptor ID |
D019459
|
MeSH Number(s) |
A10.272.850
|
Concept/Terms |
Urothelium- Urothelium
- Urinary Tract Epithelium
- Epithelium, Urinary Tract
|
Below are MeSH descriptors whose meaning is more general than "Urothelium".
Below are MeSH descriptors whose meaning is more specific than "Urothelium".
This graph shows the total number of publications written about "Urothelium" by people in this website by year, and whether "Urothelium" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 2 | 2 |
2000 | 1 | 0 | 1 |
2001 | 1 | 2 | 3 |
2005 | 0 | 2 | 2 |
2006 | 1 | 1 | 2 |
2007 | 1 | 3 | 4 |
2008 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2010 | 0 | 3 | 3 |
2011 | 2 | 0 | 2 |
2012 | 4 | 4 | 8 |
2013 | 1 | 1 | 2 |
2014 | 4 | 0 | 4 |
2015 | 1 | 2 | 3 |
2016 | 3 | 0 | 3 |
2018 | 2 | 0 | 2 |
2020 | 1 | 0 | 1 |
2021 | 1 | 2 | 3 |
2022 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Urothelium" by people in Profiles.
-
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. JCO Precis Oncol. 2023 Jul; 7:e2300095.
-
Flat intraurothelial lesions of the urinary bladder-do hyperplasia, dysplasia, and atypia of unknown significance need to exist as diagnostic entities? and how to handle in routine clinical practice. Mod Pathol. 2022 10; 35(10):1296-1305.
-
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Adv Anat Pathol. 2021 Jul 01; 28(4):179-195.
-
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):872-882.
-
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 04; 22(4):525-537.
-
FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. Front Immunol. 2020; 11:575258.
-
Contemporary Grading and Staging of Urothelial Neoplasms of the Urinary Bladder: New Concepts and Approaches to Challenging Scenarios. Surg Pathol Clin. 2018 Dec; 11(4):775-795.
-
Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. Eur J Cancer. 2018 06; 96:128-130.
-
Cancer-related microangiopathic hemolytic anemia. Transfusion. 2016 08; 56(8):1937.
-
Ubiquitination of Innate Immune Regulator TRAF3 Orchestrates Expulsion of Intracellular Bacteria by Exocyst Complex. Immunity. 2016 07 19; 45(1):94-105.